Lung Cancer Trials Ask AI to find trials
CompletedPhase 2NCT05546476
Official study title

Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15

Study summary

Study to evaluate the efficacy, safety and tolerability of ponsegromab compared to placebo in patients with cancer, cachexia, and elevated GDF 15.

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedponsegromab and Placebo for ponsegromab

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jun 3, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 2

Interventional

Where is it offered?78 U.S. locations

Locations may change over time.

Who runs it?Pfizer

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 2
Sponsor
Pfizer
Interventions being studied
Drug: ponsegromab; Drug: Placebo for ponsegromab
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Key
  • Documented active diagnosis of non-small cell lung, pancreatic, colorectal cancer
  • Cachexia defined by Fearon criteria of weight loss
  • Serum GDF-15 concentrations
  • Signed informed consent
  • ECOG PS ≤3 with life expectancy of at least 4 months to be able to complete Part A. Key
Reasons someone may not be able to joinExclusion criteria
  • Receiving tube feedings or parenteral nutrition at the time of Screening or Randomization.
  • Current active reversible causes of decreased food intake.
  • Cachexia caused by other reasons.
  • History of allergic or anaphylactic reaction to any therapeutic or diagnostic monoclonal antibody.
  • inadequate liver function
  • renal disease requiring dialysis

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • CARTI ConwayConway, Arkansas
  • CARTI Cancer CenterLittle Rock, Arkansas
  • CARTI North Little RockNorth Little Rock, Arkansas
  • CARTI StuttgartStuttgart, Arkansas
  • Pacific Cancer Medical Center INCAnaheim, California
  • Beverly Hills Cancer CenterBeverly Hills, California
  • Emad Ibrahim,MD,INC.Redlands, California
  • Providence Medical FoundationSanta Rosa, California
  • IU Health Arnett Cancer CenterLafayette, Indiana
  • Pennington Biomedical Research CenterBaton Rouge, Louisiana
  • Tandem Clinical ResearchMarrero, Louisiana
  • Bozeman Health Deaconess HospitalBozeman, Montana

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jun 3, 2026. Always confirm current availability with the study team.

View original record ↗